gastrin/cck-a

(Iso)-FK-480 is a novel orally available cholecystokinin A (CCK-A) antagonist for investigational treatment of chronic pancreatitis.

Gastrin CCK antagonist 1 is a potent gastrin CCK antagonist for the study of metabolic system-related diseases.

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).

Sograzepide (Netazepide) is an orally active, selective and highly potent gastrin CCK-B antagonist that inhibits gastrin CCK-A activity and pappalysin 2 expression in type 1 gastric neuroendocrine tumors, and can induce regression of type 1 gastric neuroendocrine tumors.

YM022 is a highly effective and selective gastrin cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.

Nastorazepide (Z-360) hemicalcium is a selective, orally-administered 1,5-benzodiazepine derivative that functions as a receptor antagonist for gastrin cholecystokinin 2 (CCK-2), exhibiting potential antitumor activity.

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

Jmv 332 is a cyclic analog of the C-terminal hexapeptide of CCK. It is a CCK/gastrin receptor agonist.

Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o

(Rac)-FK 480 may be used to study epilepsy or anxiety disorders.

L-365260 hemihydrate is a selective, orally active non-peptide gastrin and brain cholecystokinin receptor (CCK-B) antagonist, demonstrating competitive interaction with guinea pig stomach gastrin and brain CCK receptors and exhibiting inhibition constants (Kis) of 1.9 nM and 2.0 nM, respectively.

[Leu15]-Gastrin I human acetate(39024-57-2 Free base) is a peptide. It acts through G protein-coupled receptors, known as cholecystokinin (CCK) or CCK-B receptor (CCK-BR).

Caerulein, desulfated TFA is Caerulein after desulfurization.Caerulein is a deceptide with the same five carboxy-terminating amino acids as gastrin and cholecystatin (CCK)..

Nastorazepide (Z-360) is a selective, orally available antagonist of the gastrin cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity.